Russell Investments Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Russell Investments Group’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,714	Closed	-$993K	–	3269
2020 Q1	$993K	Sell	20,714 -2,280	-10%	-$106K	﹤0.01%	1844
2019 Q4	$1.08M	Buy	22,994 +18,120	+372%	+$801K	﹤0.01%	2063
2019 Q3	$115K	Buy	+4,874	New	+$144K	﹤0.01%	2793
2018 Q1	–	Sell	-42,845	Closed	-$363K	–	3061
2017 Q4	$363K	Buy	42,845 +33,998	+384%	+$418K	﹤0.01%	2527
2017 Q3	$129K	Sell	8,847 -40,736	-82%	-$616K	﹤0.01%	2742
2017 Q2	$929K	Buy	49,583 +28,632	+137%	+$646K	﹤0.01%	2148
2017 Q1	$446K	Buy	+20,951	New	+$401K	﹤0.01%	2467

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Russell Investments Group's RARX Position: Q2 2020 in Review

Russell Investments Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 20,714 shares — an estimated $993K sold.

Russell Investments Group first reported a position in RARX in Q1 2017 and held it in 7 quarters. The position peaked at $1.08M in Q4 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Russell Investments Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Russell Investments Group sold 20,714 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $993K.
Russell Investments Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2017 and held it in 7 quarters.
Russell Investments Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $1.08M in Q4 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Russell Investments Group's 13F filing for Q2 2020, filed 5 Aug 2020.